Archive for October, 2008
October 9th, 2008. Health Effects of Nanoparticles and Nanomaterials (III)
Recent reports suggest that carbon nanotubes, fiber-shaped biopersistent nanoparticles, resemble asbestos in the pathogenesis of granuloma and mesothelioma. As such we summarize health effects of environmental and manufactured nanoparticles in the literature so far including our studies, in this report.
October 9th, 2008. Peritoneal Mesothelioma
To date there have been no universally accepted treatments for MPM. Unless referred to a specialty center, patients are routinely treated with pemetrexed and cisplatin which has been shown to increase survival in pleural mesothelioma.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, mitomycin-C, Pemetrexed (Alimta), Peritoneal (Abdominal Mesothelioma), Surgery, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | 1 Comment »
October 8th, 2008. Acute abdomen in an asbestos factory worker
We treated a man who had a primary peritoneal mesothelioma with an unusual presentation — an acute abdomen. We report this case and discuss the relevant literature.
October 8th, 2008. Mesothelioma and Environmental Exposure: A Newly Developed Animal Model for Fiber Exposure
Following the 12-month exposure, lack of mesothelioma induction was detected in all groups. Results suggest that the mechanism of mesothelioma formation is not a consequence of peritoneal physical exposure to the fibers.
October 8th, 2008. Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma
04). These results suggest that NAT2 polymorphisms do not exert a strong effect on individual susceptibility to MM.
October 8th, 2008. Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin
Conclusion: The combination of gemcitabine and carboplatin is a safe and tolerable treatment with reasonable response rate, OS, and PFS compared with the historical phase II single agents and combined chemotherapy studies in patients with MPM.
October 7th, 2008. CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma
Conclusion: CK5/6 reactivity was found in a considerable proportion of metastatic adenocarcinomas of pulmonary and nonpulmonary origin. The high reactivity rate in pulmonary adenocarcinomas disagrees with the results obtained with histologic sections from solid tumor tissue, and CK5/6 seems to be of very limited value as an additional marker in effusion cytology.
October 7th, 2008. Functional inactivation of NF2/merlin in human mesothelioma
Our results support the hypothesis that the disruption of NF2 signalling is essential for the development of human mesothelioma. In tumors where no NF2 truncation can be detected, NF2 is rendered inactive by phosphorylation of Ser 518 and this can be explained at least in part by an increased expression of CPI-17.
October 4th, 2008. Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma
Conclusions: The current results suggested that HuR plays a role in tumor progression in mesothelioma and that COX-2 may be a target of its activity in neoplastic cells. Together, these observations indicate that strategies aiming toward the modulation of HuR may have a potential clinical benefit in mesothelioma.
October 3rd, 2008. Transesophageal Endoscopic Ultrasound with Fine Needle Aspiration in the Preoperative Staging of Malignant Pleural Mesothelioma
Conclusions: EUS-FNA is feasible and sensitive for MLN staging in patients with MPM who are candidate for multimodality treatment. These data warrant further evaluation.
October 2nd, 2008. Asbestos disease in Australia: looking forward and looking back
The campaign to "Make James Hardie Pay" as well as the efforts of workers and advocates are profiled in this article as well as in this issue's Documents and Voices sections. Discussion of recent developments in asbestos-related disease research and mesothelioma surveillance is followed by articulation of the comprehensive public and social health response that is needed to fully engage and address the asbestos disease legacy and to apply lessons learned to help revive the currently waning societal commitment to occupational health and safety in Australia and elsewhere.
October 2nd, 2008. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma
Conclusion: These results suggest that Hsp90 is strongly associated with the growth and survival of MM and that inhibition of Hsp90 may have therapeutic potential in the treatment of MM.
October 2nd, 2008. Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
Pemetrexed, a multitargeted antifolate agent, has shown clear activity in several tumors, including mesothelioma and NSCLC. In a phase III trial, second-line treatment with pemetrexed demonstrated overall survival comparable to docetaxel, with a more manageable toxicity profile.
Posted in Bevacizumab (Avastatin), Carboplatin, Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Docetaxel (Taxotere), Full Archive, Gemcitabine (Gemzar), paclitaxel, Pemetrexed (Alimta), Treatment, Type of Assessment: | No Comments »
|
|  |
